Cargando…

A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies

BACKGROUND: To establish a nomogram for predicting the outcome of EGFR-mutated lung adenocarcinoma patients with brain metastases (BMs) and to estimate the efficacy of different therapeutic strategies. METHODS: The data of 129 cases with BM from the period between January 1st 2011 and December 31st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jing, Zhang, Baozhong, Pang, Qingsong, Zhang, Tian, Chen, Xi, Er, Puchun, Wang, Yuwen, You, Jinqiang, Wang, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947515/ https://www.ncbi.nlm.nih.gov/pubmed/33717561 http://dx.doi.org/10.21037/jtd-20-1587

Ejemplares similares

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases
por: Wang, Jing, et al.
Publicado: (2020)

Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
por: Er, Puchun, et al.
Publicado: (2017)

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy
por: Er, Puchun, et al.
Publicado: (2020)

Chemoradiotherapy-Induced CD4(+) and CD8(+) T-Cell Alterations to Predict Patient Outcomes in Esophageal Squamous Cell Carcinoma
por: Chen, Xi, et al.
Publicado: (2019)

High expression of FUNDC1 predicts poor prognostic outcomes and is a promising target to improve chemoradiotherapy effects in patients with cervical cancer
por: Hou, Hailing, et al.
Publicado: (2017)

Nomograms for predicting progression and efficacy of post-operation radiotherapy in IIIA-pN2 non-small cell lung cancer patients
por: Zhang, Baozhong, et al.
Publicado: (2017)

Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
por: Zhang, Guojin, et al.
Publicado: (2020)

NS1-binding protein radiosensitizes esophageal squamous cell carcinoma by transcriptionally suppressing c-Myc
por: Wang, Yuwen, et al.
Publicado: (2018)

The Incidence of EGFR-Activating Mutations in Bone Metastases of Lung Adenocarcinoma
por: Krawczyk, Paweł, et al.
Publicado: (2013)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Predictive value of EGF and uPAR for chemoradiotherapy response and survival in patients with esophageal squamous cell carcinoma
por: Chen, Xi, et al.
Publicado: (2020)

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2021)

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival
por: Stanic, Karmen, et al.
Publicado: (2014)

Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
por: Schaller, Alexandre, et al.
Publicado: (2014)

Concurrent or Sequential Chemoradiotherapy after 3-4 Cycles Induction Chemotherapy for LS-SCLC with Bulky Tumor
por: Zhao, Jingjing, et al.
Publicado: (2020)

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
por: Zhang, Jinyao, et al.
Publicado: (2021)

Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status
por: Chen, Hsi-Chieh, et al.
Publicado: (2019)

Radiomic Feature-Based Nomogram: A Novel Technique to Predict EGFR-Activating Mutations for EGFR Tyrosin Kinase Inhibitor Therapy
por: Weng, Qiaoyou, et al.
Publicado: (2021)

Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations
por: Geng, Yimeng, et al.
Publicado: (2020)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature
por: Guo, Qiang, et al.
Publicado: (2023)

Miliary brain metastases from lung adenocarcinoma with EGFR (L858R) and CTNNB1 mutations
por: Kunishige, Michihiro, et al.
Publicado: (2023)

The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study
por: Liu, Yuting, et al.
Publicado: (2021)

Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma
por: Li, Changhui, et al.
Publicado: (2019)

EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
por: Ren, Yaoyao, et al.
Publicado: (2015)

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1‐ALK fusion
por: Yin, Qiang, et al.
Publicado: (2021)

Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2013)

Construction and Verification of Nomogram Model for Lung Adenocarcinoma With ≤ 5 Bone-Only Metastases Basing on Hematology Markers
por: Meng, Chunliu, et al.
Publicado: (2022)

CT imaging-based histogram features for prediction of EGFR mutation status of bone metastases in patients with primary lung adenocarcinoma
por: Shen, Tong-xu, et al.
Publicado: (2019)

Sequential occurrence of T790M mutation and small cell lung cancer transformation in EGFR-positive lung adenocarcinoma: A case report
por: Hong, Er, et al.
Publicado: (2022)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Value of (18)F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations
por: Yang, Bin, et al.
Publicado: (2020)

Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report
por: Kong, Chen, et al.
Publicado: (2020)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
por: Li, Yibin, et al.
Publicado: (2022)

Establishment of prognostic nomograms for predicting the progression free survival of EGFR‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs
por: Du, Xinyang, et al.
Publicado: (2022)

The Characteristics and Nomogram for Primary Lung Papillary Adenocarcinoma
por: Zhang, Yuqian, et al.
Publicado: (2020)

Development of a Nomogram Based on 3D CT Radiomics Signature to Predict the Mutation Status of EGFR Molecular Subtypes in Lung Adenocarcinoma: A Multicenter Study
por: Zhang, Guojin, et al.
Publicado: (2022)

Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma
por: Ma, Xiaoyan, et al.
Publicado: (2016)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1975bsvndgqu05bpki7skush7f